<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients on peritoneal dialysis experience <z:mp ids='MP_0001845'>inflammation</z:mp> associated with advanced <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> and the therapy itself </plain></SENT>
<SENT sid="1" pm="."><plain>An important consequence of the <z:mp ids='MP_0001845'>inflammation</z:mp> may be acceleration of the rate of decline in residual renal function </plain></SENT>
<SENT sid="2" pm="."><plain>The decline in residual renal function has been associated with an increased mortality for patients in this population </plain></SENT>
<SENT sid="3" pm="."><plain>Bardoxolone <z:chebi fb="36" ids="29309">methyl</z:chebi> is a synthetic <z:chebi fb="0" ids="36615">triterpenoid</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>To date, the effects of bardoxolone <z:chebi fb="36" ids="29309">methyl</z:chebi> on kidney function in humans have been studied in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>A large-scale event-driven study of bardoxolone <z:chebi fb="36" ids="29309">methyl</z:chebi> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> with stage 4 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> is underway </plain></SENT>
<SENT sid="6" pm="."><plain>The safety of bardoxolone <z:chebi fb="36" ids="29309">methyl</z:chebi> has not been evaluated in patients with more advanced (stage 5) <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> or patients on dialysis </plain></SENT>
<SENT sid="7" pm="."><plain>This report describes a proposed double blind, prospective evaluation of bardoxolone <z:chebi fb="36" ids="29309">methyl</z:chebi> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> receiving peritoneal dialysis </plain></SENT>
<SENT sid="8" pm="."><plain>In addition to assessing the safety of bardoxolone <z:chebi fb="36" ids="29309">methyl</z:chebi> in this population, the study will evaluate the effect of bardoxolone <z:chebi fb="36" ids="29309">methyl</z:chebi> on residual renal function over 6 months as compared to placebo </plain></SENT>
</text></document>